secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2023-10-13T23:59:59+00:00
Accession:  0001104659-23-109133
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports RZ358 resolves hypoglycemia in tumor-mediated hyperinsulinism patient
--------------------------------------------------------------------------------

- RZ358 administered on compassionate-use basis to patient with refractory hypoglycemia due to metastatic insulin-secreting cervical cancer.
- Treatment started September 2023; resulted in resolution of hypoglycemia and enabled hospital discharge to resume cancer therapy.
- Prior metastatic insulinoma patient has remained on RZ358 for nearly a year; case published in NEJM (389;8).
- Company sees RZ358 as potential universal treatment for hyperinsulinism; evaluating next steps in additional indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923109133/0001104659-23-109133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465923109133/tm2328296d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-109133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer